Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D3-GPC2-PBD
- Development stage
- Preclinical
- Lead developer
- Children's Hospital of Philadelphia
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
D3-GPC2-PBD is an antibody-drug conjugate (ADC) targeting glypican 2 (GPC2), a cell-surface oncoprotein highly expressed in neuroblastoma and other MYCN-driven cancers. The ADC consists of a human monoclonal antibody (D3) specific to a conformational epitope of GPC2, conjugated to a pyrrolobenzodiazepine (PBD) dimer payload. Upon binding and internalization, the PBD payload induces potent DNA damage, leading to apoptosis and immunogenic cell death. It has demonstrated significant efficacy in patient-derived xenograft models of neuroblastoma and small-cell lung cancer (SCLC). The drug was developed through a collaboration involving the Children’s Hospital of Philadelphia and other academic institutions.
- Other names
- D3-GPC2 ADCD-3-GPC2 ADCD 3-GPC2 ADCGPC2-PBD ADCGPC-2-PBD ADCGPC 2-PBD ADC
02
Targets
DNAGPC2 (Glypican-2)
Beyond the preview
Go deeper on D3-GPC2-PBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D3-GPC2-PBD.